Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598596 · ClinicalTrials.gov registry record · Phase 2
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
A Phase 2 study, sponsored by Ampel BioSolutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT02598596 is a Phase 2 study that has completed, run by Ampel BioSolutions. The registered enrollment target is 132 participants.
The verdict
NCT02598596, a Phase 2 study, has completed, sponsored by Ampel BioSolutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.
Interventions
- DRUG Azathioprine
- BIOLOGICAL Pegloticase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2015-12 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02598596
The ClinicalTrials.gov registry entry for NCT02598596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampel BioSolutions, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azathioprine is the first listed.
NCT02598596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02598596 about?
NCT02598596 is a clinical study titled "Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect". The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.
What is the current status of trial NCT02598596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2015-12. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT02598596?
The interventions under investigation include: Azathioprine (DRUG), Pegloticase (BIOLOGICAL).
Who is sponsoring clinical trial NCT02598596?
This trial is sponsored by Ampel BioSolutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.